Understanding_the_selective_consequences_of_mass_azithromycin_administration_on_the_genomic_population_structure_of_Treponema_pallidum-sc-6297
Understanding_the_selective_consequences_of_mass_azithromycin_administration_on_the_genomic_population_structure_of_Treponema_pallidum
Mass azithromycin administration forms a key element of the WHO Yaws elimination strategy, yet the long-term consequences of MDA on bacterial population structure are still poorly understood. We will sequence T. pallidum from a large Yaws MDA campaign to understand the population structure and transmission dynamics resulting from azithromycin selection. Aims and Objectives: To study the long term consequences of mass azithromycin administration on the population structure and transmission dynamics of yaws. Sample Size: Up to 270 samples will be sequenced by ISC pulldown on Illumina. Sample Processing: Pre-extracted gDNA from a large MDA trial has been prepared by our collaborators at Masaryk University (Czech Republic), and will be shipped to the Wellcome Sanger Institute for sequencing. The chief investigator and the research team of the principal investigator at the WSI will have access to the samples. DNA from the nucleic acid extracts will be quantified by qPCR, normalised/pooled according to pathogen load, and metagenomic libraries enriched for Treponema DNA reads will be prepared using established ISC protocols at WSI. Sequencing will be done on Illumina HiSeq 4000. Data analysis: Enriched metagenomic sequencing reads will be pre-processed and binned using in-house pipelines. Treponema reads will be mapped to reference genomes, SNPs and INDELS called, and compared in phylogenomic analysis as previously. Outputs: The data from this study will form a key part of our ongoing Treponema project, and would be expected to generate at least one high impact publication, as well as providing a springboard to more focused, functional characterisation either at WSI or elsewhere. The data will be made fully available to the research community for further analysis. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
Mass azithromycin administration forms a key element of the WHO Yaws elimination strategy, yet the long-term consequences of MDA on bacterial population structure are still poorly understood. We will sequence T. pallidum from a large Yaws MDA campaign to understand the population structure and transmission dynamics resulting from azithromycin selection.